throbber

`
`
` B
`
` &H-ACC-NO: 53367226
`
`
`DOC-REF-NO: IMK-2100-27
`
`LENGTH: 948 words
`
`HEADLINE: Smooth operators
`
`HEADNOTE:
`Pharmaceutical sales reps succeed by offering the right incentives to physicians
`
`ABSTRACT:
`If there is a prescription for success in selling pharmaceuticals, it is probably to offer doctors meaningful incentives
`that help forge friendly relationships with them. For years, physicians have been showered with all sorts of incentives
`by drug companies, but as the growth of the pharmaceutical industry escalates - and the competition among opposing
`sales representatives gets more intense - it is the one-to-one relationship between a sales rep and a physician that is
`becoming critical. A recent report by ABC News stated that pharmaceutical companies spent an average of $13,000 on
`every physician in the country last year, which adds up to more than $8 billion. Furthermore, drug companies now
`employ about 70,000 sales reps - or one for every 9 doctors. Yet many of these reps could stand to improve their sales
`techniques.
`
`BODY:
`If there's a prescription for success in selling pharmaceuticals, it's probably to offer doctors meaningful incentives
`that help forge friendly relationships with them. For years physicians have been showered with all sorts of incentives by
`drug companies, but as the growth of the pharmaceutical industry escalates-and the competition among opposing sales
`representatives gets more intense-it's the one-to-one relationship between a sales rep and a physician that is becoming
`crucial.
`"The problem in pharmaceutical sales is the impression that because the time spent with a physician is short, the
`relationship is less necessary to emphasize," says Dr. Charles E. Parker, a Virginia Beach, Va.-based psychiatrist and
`president of PharmaceuticaIU.com, a virtual training Web site for pharmaceutical sales reps. "But the reality is just the
`opposite. The shorter the time, the more you have to emphasize the relationship. A lot of reps really don't know how to
`do it."
`If they don't, they'd better learn fast. The pharmaceutical industry has been growing by leaps and bounds in recent
`years. According to the Plymouth Meeting, Pa.-based IMS Health, a healthcare information company, more than $125
`billion was spent on prescription medication last year in the United States (up from just $89 billion in 1997).
`
`2 of 2 DOCUMENTS
`
`Copyright 2000 Bell & Howell Information and Learning
`ABI/INFORM
`Copyright 2000 Bill Communications
`Incentive
`
`May, 2000
`
`
`
`
`SECTION: Vol. 174, No. 5; Pg. 104-105; ISSN: 10425195
`
`IMMUNOGEN 2286, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`

`

`Incentive May, 2000
`
`Page 2
`
`The importance of establishing direct relationships with physicians-who, of course, are the ones actually writing the
`prescriptions-is certainly not lost on the drug companies. A recent report by ABC News stated that pharmaceutical
`companies spent an average of $13,000 on every physician in the country last year, which adds up to more than $8
`billion. Furthermore, drug companies now employ about 70,000 sales repsor one for every nine doctors. Yet many of
`these reps could stand to improve their sales techniques.
`Personalization is key
`"The biggest thing with incentives is the personalization and customization of the item offered," says Parker. "I've
`seen reps give the standard fruit basket. Now I can't speak for physicians across the board, but when I receive a fruit
`basket it feels like I'm being depersonalizedand being bought."
`What works a lot better in Parker's case is a genuine appeal to his interests. And one of his biggest interests happens
`to be fly-fishing. "Anybody that's spent a minimum amount of time with me knows that," he says. "I have a flyrod on
`my wall."
`So while a fruit basket will likely end up in his wastebasket, a more thoughtful fly-fishing-related item could
`become a treasure. "A $2 fly will go a long way with me," he says. "I don't think it's a money thing, I think it's a
`personalization and customization thing. The more personalized it is, the more effective it is. If they've hit me right in
`my heart, it's an emotional connection."
`Trying to establish that emotional connection can occasionally cost some money, although the American Medical
`Association's (AMA) guidelines limit the suggested value of an incentive to less than $100. If reps exceed that limit, the
`AMA's guidelines state that the incentive should serve a genuine "educational function."
`Katie Clark, a former pharmaceutical sales rep and now a senior account executive at DVC ActiveCare, a
`Morristown, N.J.-based marketing company that specializes in the healthcare industry, says that a drug company's
`profits are directly linked to the rep-physician relationship. "If a physician sees product A and product B as more or less
`effective, and if he sees no difference between them, then it will come down to which rep he uses more often . . . which
`one he likes better personally," she says.
`Clark, who specialized in medications used for treating HIV and cystic fibrosis when she was a rep, says she often
`supplied lunch for the physicians she was trying to get to know better. "It was helpful if you brought in lunch, but not
`mandatory," she says of her meetings with cystic fibrosis physicians. But the same was not true for the HIV specialists.
`"In HIV, you have to bring in lunch if you expect to talk to the physician," she says. Because HIV doctors must contend
`with a whole slew of maladies affecting all areas of a patient's body, they are continually being approached by a variety
`of sales reps. Each physician's time is subsequently.that much more precious, so the incentives offered by a rep must be
`extra special. Bringing in lunch is the bare minimum. "The competition is very stiff," says Clark.
`In the end, though, no matter how wonderful an incentive may be, it's the scientific research behind a medication
`that's the bottom line. "That's what really sways the physician," says Parker.
`Clark concurs. "The incentives will help you along, but the scientific backing of the drug is what's really going to
`help the physician decide," she says.
`
`LOAD-DATE: May 22, 2000
`
`
`IMMUNOGEN 2286, pg. 2
`Phigenix v. Immunogen
`IPR2014-00676
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket